TScan Therapeutics, Inc.TCRXNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -90.78% | +283.57% | +473.88% | +139.37% | +286.02% |
| Gross Profit Growth | -88.79% | +283.57% | +473.88% | +66.25% | +177.29% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +27.37% | +36.68% | +14.38% | +9.38% | +7.51% |
| Weighted Average Shares Diluted Growth | +27.37% | +36.68% | +14.38% | +9.38% | +7.51% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +36.37% | +38.15% | -20.36% | -24.65% | -38.35% |
| Book Value per Share Growth | +25.40% | +25.07% | -39.46% | -42.52% | -52.47% |
| Debt Growth | +5.35% | +5.75% | +2.13% | +5.83% | -3.33% |
| R&D Expense Growth | +31.01% | +19.84% | +21.42% | +18.41% | -31.73% |
| SG&A Expenses Growth | +49.43% | +22.53% | +17.51% | +3.90% | -12.46% |